12 completed. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 12 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow vaxigrip: new trials by email Literature Review of vaxigrip trials Research Report on vaxigrip
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI) Allantoic Split Inactivated Seasonal flu Vaccine, VAXIGRIP - Influenza | Phase 2 | Completed | Research Institute for Biological Safety Problems | 300 | 2016-10-01 | 2018-06-07 |
| Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa Adjuvanted seasonal trivalent inactivated influenza vaccine, Seasonal trivalent inactivated influenza vaccine, Saline (bacteriostatic 0.9% sodium chloride for injection) - Influenza | Phase 2 | Completed | PATH | 296 | 2013-04-01 | 2013-10-22 |
| Routes of Immunization and Flu Immune Responses INTANZA® 15, Vaxigrip®, INTANZA® 15 T - Influenza | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 60 | 2012-10-01 | 2013-08-05 |
| Influenza Vaccination of HIV Infected Pregnant Women: Safety and Immunogenicity Trivalent influenza vaccine, Normal saline - Influenza | Phase 2 / Phase 3 | Completed | University of Witwatersrand, South Africa | 194 | 2011-03-01 | 2013-02-07 |
| A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Placebo - Influenza | Phase 1 / Phase 2 | Completed | BiondVax Pharmaceuticals ltd. | 60 | 2009-09-01 | 2012-07-31 |
| Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore CYD Dengue vaccine, NaCl + influenza virus or hepatitis A vaccine - Dengue Fever, Dengue Hemorrhagic Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1198 | 2009-04-07 | 2022-03-21 |
| Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control GSK Biologicals' influenza vaccine GSK1557482A, Vaxigrip - Influenza | Phase 2 | Completed | GlaxoSmithKline | 390 | 2008-11-10 | 2018-08-17 |
| Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects Inactivated, split-virion influenza virus - Influenza, Orthomyxoviridae Infections | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 62 | 2007-11-01 | 2014-01-14 |
| Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines Inactivated, split-virion, influenza vaccine, Inactivated, split-virion influenza vaccine - Influenza, Orthomyxovirus Infections | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 160 | 2007-09-01 | 2015-06-17 |
| A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine Inactivated influenza vaccine (split virion) NH 2007-2008 formulation - Influenza, Orthomyxoviridae Infections | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 130 | 2007-06-01 | 2014-01-17 |
| Immunogenicity Study of the Influenza Vaccine in Adults Inactivated, split-virion influenza vaccine, Inactivated, split-virion, influenza virus - Orthomyxoviridae Infections, Influenza | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 978 | 2005-09-01 | 2014-01-14 |
| Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adults Inactivated, split-virion influenza vaccine - Influenza, Orthomyxoviridae Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 1150 | 2003-09-01 | 2014-01-13 |
Influenza, Human (11) · Orthomyxoviridae Infections (5) · Dengue (1) · Severe Dengue (1) · Virus Diseases (1)
Sanofi Pasteur, a Sanofi Company (6) · Assistance Publique - Hôpitaux de Paris (1) · BiondVax Pharmaceuticals ltd. (1) · GlaxoSmithKline (1) · PATH (1) · Research Institute for Biological Safety Problems (1) · University of Witwatersrand, South Africa (1)
France (3) · Belgium (2) · Canada (1) · Czechia (1) · Germany (1) · Israel (1) · Kazakhstan (1) · Lithuania (1) · Senegal (1) · Singapore (1) · South Africa (1) · Switzerland (1) · United Kingdom (1)
Adriana Weinberg, PhD (1) · Aldiouma Diallo, MD (1) · Berik M Khairullin, PhD (1) · Jacob Atsmon, MD (1) · John C Victor, PhD, MPH (1) · Keith P Klugman, MD, PhD (1) · Shabir A Madhi, MD, PhD (1)
PMID 19261173, PMID 19341446, PMID 22894958, PMID 23687572, PMID 23839107, PMID 25184864, PMID 25483667, PMID 28369198, PMID 29253090, PMID 30224199, PMID 30843873, PMID 32048890, PMID 38743692
2014 (1)